Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Monocytes + Sylatron + Actimmune in Recurrent/Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02948426Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Feb 2017
- Primary completion
- Sep 2020
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous monocytes, peginterferon alfa-2b and interferon gamma-1b in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (5 arms), sponsored by National Cancer Institute. Primary endpoints: Overall Maximum Tolerated Dose of Intraperitoneal Autologous Monocytes, Overall Maximum Tolerated Dose of Sylatron (Peginterferon Alpha-2b) and 1 more. Started Feb 2017; status: terminated.
02
Drugs
autologous monocytespeginterferon alfa-2binterferon gamma-1b
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02948426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02948426.